Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2023-04-19 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
独立董事辞职公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of an independent director from the company's board. It details the resignation date, reasons, and impact on the board composition. There is no financial data, no mention of financial results, no report attached or referenced as being published, and no regulatory certification. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-04-19 Chinese
关于召开 2022 年年度股东大会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a notice announcing the convening of the 2022 Annual General Meeting (AGM) of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the meeting date, voting methods, agenda items to be discussed, and other procedural information. It references various reports and announcements that have been or will be disclosed elsewhere, but does not contain the reports themselves. The document is about the AGM meeting logistics and agenda, not the actual annual report or financial statements. Therefore, it fits the category of AGM Information (AGM-R). The document length is 4568 characters, which is consistent with a detailed AGM notice rather than a full report.
2023-04-19 Chinese
独立董事候选人声明（任涛）
Board/Management Information Classification · 95% confidence The document is a formal declaration by an independent director candidate (任涛) for Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the candidate's qualifications, independence, and compliance with relevant laws and regulations for serving as an independent director. There are no financial statements, earnings data, or report attachments. The document is a regulatory announcement related to board/management information, specifically about a director candidate's declaration. It does not fit into categories like Annual Report, Earnings Release, or Proxy Solicitation. The best fitting category is Board/Management Information (MANG). The document length is short and focused on management nomination and qualifications, confirming this classification.
2023-04-19 Chinese
第四届董事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 13th meeting of the 4th Board of Directors of Guangdong Yongshun Biopharmaceutical Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to other reports and announcements published on the Beijing Stock Exchange website. The content focuses on board meeting decisions, including reports, financial budgets, credit applications, director appointments, and governance matters. It does not contain the full text of any financial report or detailed financial data itself but rather the board's resolutions and approvals. This type of document is best classified as Board/Management Information (MANG) because it announces changes and decisions made by the board and senior management rather than being a full financial report or other filing type.
2023-04-19 Chinese
中信建投证券股份有限公司关于广东永顺生物制药股份有限公司公司治理自查和规范活动的专项核查意见
Regulatory Filings
2023-04-19 Chinese
董事任命公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of new directors to the company's board, including details about the nominees, their qualifications, and the legal compliance of the appointment process. It references the company's board meeting resolutions and independent directors' opinions. There is no financial data, earnings information, or report publication mentioned. The content clearly fits the category of announcements about changes in the company's board of directors. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 2503 characters, which is consistent with a detailed announcement rather than a full report.
2023-04-19 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.